Printer Friendly


 PRINCETON, N.J., Oct. 8 /PRNewswire/ -- A novel nasal spray analgesic delivers postoperative pain relief benefits compatible with the goals of the Department of Health and Human Services guidelines for the modernization of pain management, said Therese K. Abboud, M.D., professor of anesthesiology, LAC/USC Medical Center, Women's Hospital, Los Angeles.
 Abboud is an author of several studies including "Transnasal butorphanol: a new method for pain relief in post-cesarean section pain."
 Abboud addressed the compatibility of the novel nasal spray analgesic and the pain management guidelines during the recent Mead Johnson Laboratories Update Conference: Overview of Pain Management, held in Atlanta. The Agency for Health Care Policy and Research (AHCPR) of the U.S. Department of Health and Human Services (USDHHS) designed clinical practice guidelines to help clinicians, patients and patients' families better understand the assessment and treatment of postoperative and other acute pain.
 To develop the guidelines, an interdisciplinary panel was convened, including physicians, nurses, a pharmacist, a psychologist, a physical therapist, a patient and a medical ethicist. The development process included an extensive review of patient needs, therapeutic practices, emerging technologies, and the literature on pain management. In addition, opinions were obtained from external consultants and an open hearing was held in Washington. Then, drafts of the guidelines were peer reviewed and field tested.
 The four major goals of the guidelines are to:
 -- reduce the incidence and severity of acute postoperative and posttraumatic pain;
 -- educate patients about communicating their unrelieved pain to physicians, nurses and family members;
 -- enhance patient comfort and satisfaction, and
 -- contribute to fewer postoperative complications and shorter hospital stays.
 Patients vary widely in their responses to pain and to treatment strategies. Therefore, the guidelines also recommend a flexible and aggressive approach to pain management that can be used in daily clinical practice.
 Abboud has found that the benefits of providing postoperative pain relief with butorphanol tartrate nasal spray are compatible with the AHCPR goals.
 The doctor refers to several clinical studies that have demonstrated butorphanol tartrate nasal spray to be efficacious in relieving moderate-to-severe postsurgical pain thereby reducing the severity of postopeative pain. Abboud said she believes the new nasal spray's rapid and convenient 15-minute onset of action allows effective pain control.
 In addition to controlling pain, Abboud points to preventing recurrence as an important goal of the guidelines. Because the nasal spray formulation enables a patient to self-administer the butorphanol tartrate analgesic, there is, in effect, intermittent patient-controlled analgesia. When pain does not recur due to timely self-administration of analgesia, Abboud believes patient comfort and satisfaction are enhanced.
 The guidelines also call for effective pain management that contributes to shorter hospital stays. The doctor noted that effective pain relief can lead to a patient becoming ambulatory earlier and consequently to an abbreviated hospital sojourn. Butorphanol tartrate nasal spray administered on an outpatient basis can be an important part of an effective pain management plan, Abboud said.
 Modernizing their pain management approaches should be a goal of today's practicing physicians, particularly in light of new developments such as the nasal spray analgesic, said Abboud.
 The efficacy, rapid onset, convenient administration and moderate sedative properties of butorphanol tartrate nasal spray make it an important alternative to oral opioid analgesics for the outpatient management of pain. Patients are cautioned about possible drowsiness and are told to lie down and try to sleep after taking a dose.
 Mead Johnson Laboratories, a division of Bristol-Myers Squibb (NYSE: BMY), is dedicated to excellence in women's healthcare, and markets, among other products, Stadol(R) NS(TM) (butorphanol tartrate nasal spray), the first and only non-federally controlled nasal spray analgesic for rapid and effective relief of acute pain.
 Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological therapies, diagnostic agents and non- prescription medicines.
 -0- 10/8/93
 /CONTACT: Patrick Donohue of Bristol-Myers Squibb, 609-252-5685, or Chilton G. Goebel Jr., APR, of Harris, Baio & McCullough, 215-400-9800, for Bristol-Myers Squibb/

CO: Bristol-Myers Squibb ST: New Jersey IN: MTC SU:

CC-MK -- PH018 -- 0227 10/08/93 14:21 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1993

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters